Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 10, 2022 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present at Upcoming Investor Conferences

NEWARK, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
November 18, 2021 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

NEWARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative...
November 17, 2021 16:33 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

NEWARK, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative...
November 15, 2021 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Long-term Open Label Study Finds Treatment with Seladelpar for Two Years Improves Key Liver Biomarkers in Patients with PBC

Study results presented at The Liver Meeting® 2021 demonstrated continued reductions in biomarkers of cholestasis and hepatocellular injury over two yearsSeladelpar generally appeared safe with low...
November 11, 2021 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Host Post-AASLD Key Opinion Leader Webinar on Seladelpar for Primary Biliary Cholangitis

NEWARK, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
November 10, 2021 16:06 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Reports Third Quarter and Nine Months Ended September 30, 2021 Financial Results and Provides Corporate Update

Over 100 clinical sites now activated in RESPONSE Phase 3 registration study of seladelpar for patients with primary biliary cholangitis (PBC) Additional data from prior studies of seladelpar in...
November 04, 2021 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present at Upcoming Investor Conferences

NEWARK, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
November 03, 2021 16:05 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

NEWARK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
October 01, 2021 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Announces Presentations at The Liver Meeting® 2021

NEWARK, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
August 30, 2021 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present at Upcoming Investor Conferences

NEWARK, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right